Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bioverativ Therapeutics Inc.
Participants will follow either a prophylaxis or on-demand regimen. The starting dose in this study will be determined by the clinical profile of the patient in the preceding studies, B-LONG 998HB102 (NCT01027364) and Kids B-LONG study 9HB02PED (NCT01440946)
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Subjects who have completed studies 998HB102 (NCT01027364) or 9HB02PED (NCT01440946) or other studies with rFIXFc
Ability to understand the purposes \& risks of the study and provide signed and dated informed consent.
You may not be if
High-titer inhibitor (\>/=5.00 BU/mL)
Clareo Health | Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
